Chemical Namegilteritinib
Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
CompanyAstellas Pharma Inc.
Approval Year2018


  • To treat refractory or relapsed acute myeloid leukemia in adults with a FLT3 mutation.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xospata (Gilteritinib) Prescribing Information 2018Astellas Pharma US, Inc, Northbrook, IL